Figure 4

Repeated and higher doses of AZD8601 had greater effects on diabetic wound healing. (A) Dosing on days 0 and 3 increased early healing compared to dosing on day 0 only (n = 7–8/group). (B) The greatest effect on wound closure was achieved by the 200 µg dose of AZD8601, which came closest to replicating the effect of exogenous recombinant VEGF-A165 protein positive control (n = 6/group). *p < 0.05, **p < 0.01, ***p < 0.001.